A Phase 2 interventional study of botulinum toxin, Type A and Vehicle in Lateral Canthal Lines and Crow's Feet, sponsored by Eirion Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-21.
Sponsored by Eirion Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.
Eirion Therapeutics Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vehicle
Biological: Vehicle
botulinum toxin, Type A, Dose 1
Biological: botulinum toxin, Type A
botulinum toxin, Type A, Dose 2
Biological: botulinum toxin, Type A
botulinum toxin, Type A, Dose 3
Biological: botulinum toxin, Type A
botulinum toxin, Type A, Dose 4
Biological: botulinum toxin, Type A
topical liniment
Also known as: ET-01
Vehicle Formulation
Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2
Composite of Investigators Global Assessment \& Subject Self-Assessment on contraction. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be "responders" defined as Score ≤ 2.
Time frame: Week 4
Total Number of Observations With a Response Defined as IGA-C Score ≤ 2
Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.
Time frame: Week 2, 4, 8,12,18
Total Number of Observations With a Response Defined as SSA-C Score ≤ 2
Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.
Time frame: Week 2, 4, 8,12,18
| Milestone | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 |
|---|---|---|---|---|---|
| Started | 13 | 9 | 9 | 9 | 8 |
| Completed | 12 | 8 | 9 | 9 | 8 |
| Not completed | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
Composite of Investigators Global Assessment \& Subject Self-Assessment on contraction. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be "responders" defined as Score ≤ 2.
| Participants | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 |
|---|---|---|---|---|---|
| Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 | 2 | 3 | 4 | 2 | 1 |
Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.
| Observations | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 |
|---|---|---|---|---|---|
| Total Number of Observations With a Response Defined as IGA-C Score ≤ 2 | 16 | 17 | 22 | 16 | 9 |
Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.
| Observations | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 |
|---|---|---|---|---|---|
| Total Number of Observations With a Response Defined as SSA-C Score ≤ 2 | 20 | 19 | 26 | 15 | 8 |
Collected over 26 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Dose 1 | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Dose 2 | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Dose 3 | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Dose 4 | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 |
|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/13 | 0/9 | 0/9 | 0/9 | 1/8 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/9 | 1/9 | 0/9 | 0/8 |
| Age, Categorical(Participants) | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 9 | 9 | 9 | 8 | 48 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 8 | 9 | 7 | 8 | 43 |
| Male | 2 | 1 | 0 | 2 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 13 | 8 | 9 | 8 | 8 | 46 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 2 |
| Region of Enrollment(participants) | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Total |
|---|---|---|---|---|---|---|
| United States | 13 | 9 | 9 | 9 | 8 | 48 |
| IGA-C(units on a scale) | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Total |
|---|---|---|---|---|---|---|
| Mean | 3.5 ± 0.4 | 3.6 ± 0.5 | 3.4 ± 0.5 | 3.4 ± 0.5 | 3.5 ± 0.5 | 3.5 ± 0.5 |
| SSA-C(units on a scale) | Vehicle | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Total |
|---|---|---|---|---|---|---|
| Mean | 3.5 ± 0.5 | 3.6 ± 0.5 | 3.4 ± 0.5 | 3.5 ± 0.5 | 3.4 ± 0.5 | 3.5 ± 0.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Jun 2018, 7 months.
Results were first posted in Sep 2021, 3 years 2 months after primary completion. A results delay was requested in Jul 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Eirion Therapeutics Inc.